Inhibrx Biosciences, Inc. (INBX)

NASDAQ: INBX · USD

$74.7

-20.92 (-21.9%)· Recorded snapshot

Market cap	1.1B
Net income (ttm)	-138.2M
EPS (ttm)	-$8.88
Shares out	14.7M
Volume	1,146,495
Beta	3.82

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -138.2M
EPS (ttm): -$8.88
Market cap: 1.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-1,773.6

P25 n/aP50 n/aP75 n/a

ROIC-90.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All INBX indicators

Market & fundamental data

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002007919
Company name	Inhibrx Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	45720N103
Earnings date	2026-11-13
Earnings time	bmo
Employees	110
Employees change	-51
Employees growth	-31.68%
Enterprise value	$1.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2010
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-08-19
Is primary listing	Yes
Is SPAC	No
ISIN number	US45720N1037
Last 10-K release date	2026-03-19
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.1B
Market cap category	Small-Cap
Next earnings date	2026-11-13
Options	Yes
Price	$74.74
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	INBX
U.S. state	California
Website	https://inhibrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-11.88%
FCF / EV yield	-11.75%
FCF yield	-12.28%
Forward EV/Sales	176.8x
Forward P/S	169.2x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.3M
ROA	-43.61%
ROA (5Y)	-62.33%
ROCE	-101.31%
ROE	-1,773.6%
ROE (5Y)	-52.96%
ROIC	-90.13%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth	550%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-10,000
Depreciation and amortization	$2.2M
EBIT	$-127.8M
EBITDA	$-125.6M
EPS	$-8.88
FCF per share	$-8.96
Financing cash flow	$78.7M
Free cash flow	$-131.9M
Free cash flow minus SBC	$-143.6M
Gross profit	$-103M
Income taxes	$3,000
Investing cash flow	$-7,000
Net borrowing	$75M
Net cash flow	$-53.2M
Net income	$-138.2M
Operating cash flow minus SBC	$-143.6M
Operating income	$-127.8M
Stock-based compensation	$11.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-1.92
Book value per share	$-3.60
Interest coverage	-8.21
Long-term assets	$12M
Long-term liabilities	$179.1M
Net cash (debt)	$-48.3M
Net cash / market cap	-4.49%
Piotroski F-Score	2
Property, plant and equipment	$7.2M
Shareholders' equity	$-53M
Tangible book value	$-53M
Tangible book value per share	$-3.60
Total assets	$154.2M
Total cash	$133.3M
Total debt	$181.6M
Total liabilities	$207.2M
WACC	22.6%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$142.2M
Current liabilities	$28.1M
Current ratio	5.07
Inventory turnover	55.75
Net working capital	$-16.7M
Quick ratio	4.76
Working capital	$114.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.61%
Dividend yield	0%
Shareholder yield	-0.61%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$97.91
1D price change	-21.87%
1M price change	-26.61%
1M total return	-26.61%
1W price change	-23.29%
1W total return	-23.29%
1Y price change	24.21%
1Y return CAGR	24.23%
1Y total return	24.21%
20-day SMA	$91.92
200-day SMA	$92.16
3M price change	-11.34%
3M total return	-11.34%
50-day SMA	$103.44
50-day SMA vs 200-day SMA	50over200
52-week high	$155.29
52-week high date	2026-04-22
52-week low	$57.30
52-week low date	2026-03-27
6M price change	-44.39%
6M total return	-44.39%
All-time high	$155.29
All-time high date	2026-04-22
All-time low	$10.80
All-time low date	2024-08-12
Average true range (ATR)	$7.84
Average volume	256.6K
Beta (1Y)	3.06
Beta (2Y)	1.35
Beta (5Y)	3.82
Change from 52-week high	-51.87%
Change from 52-week low	30.44%
Change from all-time high	-52.93%
Change from all-time low	576.85%
Change from open	-21.72%
Day's gap	-0.19%
Dollar volume	$85.7M
High price	$95.49
Low price	$69.74
Monthly RSI	52.98
Open price	$95.48
Position in 52-week range	19.42%
Premarket change	0.88%
Premarket close	$95.66
Premarket price	$96.50
Previous close	$95.66
Price vs 150-day SMA	-25.34%
Price vs 20-day SMA	-20.47%
Price vs 200-day SMA	-20.68%
Price vs 50-day SMA	-29.33%
Relative volume	4.47
Return from IPO price	329.41%
RSI	31.73
Sharpe ratio	0.62
Sortino ratio	1.06
Volume	1.1M
Weekly RSI	39.66
YTD price change	-7.47%
YTD total return	-7.47%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8.6M
Float percentage	58.29%
Shares change (QoQ)	0.54%
Shares change (YoY)	0.61%
Shares held by insiders	15.62%
Shares held by institutions	73.6%
Shares outstanding	14.7M
Short % of float	40.01%
Short % of shares	23.32%
Short ratio	9.7 days

Deeper analysis on INBX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this INBX report

Is a complete INBX research report available?

No complete published report is available for Inhibrx Biosciences, Inc. (INBX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Inhibrx Biosciences, Inc. (INBX)

Price

Financial snapshot

Fair-value bridge

Latest news · INBX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All INBX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on INBX

Frequently asked questions